In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats

201630 citationsJournal Articlegold Open Access

Authors

David P. Gearing · Nexen (Canada)

Margie Huebner · Agricultural Research Service - Plains Area

Elena R Virtue · Nexen (Canada)

Katherine L. Knight · Nexen (Canada)

Per Brinch Hansen · Nexen (Canada)

B. Duncan X. Lascelles · University of North Carolina at Chapel Hill

R Patrick Gearing

Abstract

The high affinity, long plasma half-life, safety, and analgesic efficacy of felinized anti-NGF mAb (NV-02) support further investigation of the analgesic potential of this antibody in the cat.

Topics & Keywords

Nerve injury and regeneration Pain Mechanisms and Treatments Neuropeptides and Animal Physiology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Veterinary Internal Medicine

Volume 30, Issue 4, pp. 1129-1137

DOI: 10.1111/jvim.13985

Field-Weighted Citation Impact: 1.01